Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

@article{Bartlett1994PhaseIT,
  title={Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.},
  author={Nancy L. Bartlett and Bert L. Lum and G. A. Fisher and Nathalie Brophy and Mahdi Ehsan and J Jason Halsey and Branimir Sikic},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1994},
  volume={12 4},
  pages={835-42}
}
PURPOSE To study the effects of cyclosporine (CsA), a modulator of multidrug resistance (MDR), on the pharmacokinetics and toxicities of doxorubicin. PATIENTS AND METHODS Nineteen patients with incurable malignancies entered this phase I trial. Initially patients received doxorubicin alone (60 or 75 mg/m2) as a 48-hour continuous intravenous (i.v.) infusion. Patients whose tumors did not respond received CsA as a 2-hour loading dose of 6 mg/kg and a 48-hour continuous infusion of 18 mg/kg/d… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
66 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 66 extracted citations

Similar Papers

Loading similar papers…